Recent Advances in Nanoparticle-Based Drug Delivery Strategies to Cross the Blood–Brain Barrier in Targeted Treatment of Alzheimer’s Disease

The blood–brain barrier (BBB) is a major obstacle to the development of brain-targeted drug delivery systems, restricting greater than 98% of small molecules (<500 Da) and virtually all large-molecule drugs from entering the brain tissues from the bloodstream, resulting in suboptimal drug doses and...

Повний опис

Бібліографічні деталі

Автори:	Hoa Le, Giang T. T. Vu, Amos Abioye, Adeboye Adejare
Формат:	Artigo
Мова:	Inglês
Опубліковано:	MDPI AG 2026-02-01
Серія:	Pharmaceutics
Предмети:	blood–brain barrier tight junctions brain-targeting ligands Alzheimer’s disease amyloid-beta oligomer amyloid-beta plaque
Онлайн доступ:	https://www.mdpi.com/1999-4923/18/2/192
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!